Literature DB >> 10869747

Diffusion limited hypoxia estimated by vascular image analysis: comparison with pimonidazole staining in human tumors.

K Haustermans1, I Hofland, L Van de Pavert, K Geboes, M Varia, J Raleigh, A C Begg.   

Abstract

PURPOSE: To assess diffusion limited hypoxia in human tumors using image analysis of vasculature and to compare it with the bioreductive marker pimonidazole as an independent method.
MATERIALS AND METHODS: To set up the method, nine rectal adenocarcinomas and ten squamous cell carcinomas were analyzed. To validate the method, ten squamous cell carcinomas of the cervix were analyzed from patients who were injected with pimonidazole and biopsied approximately 24 h later. Sections of the rectal and esophageal tumors were stained for vasculature, while cervix tumor sections were double stained for vasculature and pimonidazole. Tumor areas were delineated on digitized images, and the proportion of tumor tissue greater than a fixed distance from the nearest blood vessel (called diffusion limited fraction, DLF) was then calculated. The proportion of tumor area stained for pimonidazole was also measured.
RESULTS: There was a wide variation between tumors in both the vascular-derived DLF and in the pimonidazole-stained fraction. Average DLFs varied between 1.5 and 92% for different tumors, with significant differences between them. The area stained by pimonidazole was significantly smaller than DLF for all tumors. The correlation between pimonidazole area and DLF was significant in three of seven tumors containing > or = 3 images. When images from all tumors (n=123) were analyzed together, the correlation was highly significant (r=0.47, P<0.0001).
CONCLUSION: The vascular derived DLF correlates significantly with pimonidazole staining, but there was large scatter. Both methods may underestimate perfusion limited hypoxia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869747     DOI: 10.1016/s0167-8140(00)00206-1

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  9 in total

1.  Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors.

Authors:  Tim J Kruser; Deric L Wheeler; Eric A Armstrong; Mari Iida; Kevin R Kozak; Albert J van der Kogel; Johan Bussink; Angela Coxon; Anthony Polverino; Paul M Harari
Journal:  Clin Cancer Res       Date:  2010-05-27       Impact factor: 12.531

2.  Using semi-quantitative dynamic contrast-enhanced magnetic resonance imaging parameters to evaluate tumor hypoxia: a preclinical feasibility study in a maxillofacial VX2 rabbit model.

Authors:  Linfeng Zheng; Yujie Li; Feng Geng; Sujuan Zheng; Ruiling Yan; Yuedong Han; Qiben Wang; Zhuoli Zhang; Guixiang Zhang
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

3.  Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation.

Authors:  D Vordermark; T Shibata; J M Brown
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

4.  Differential expression of HIF-1 in glioblastoma multiforme and anaplastic astrocytoma.

Authors:  Arnulf Mayer; Fabienne Schneider; Peter Vaupel; Clemens Sommer; Heinz Schmidberger
Journal:  Int J Oncol       Date:  2012-07-16       Impact factor: 5.650

5.  [18F]Fluoromisonidazole PET in rectal cancer.

Authors:  Tanuj Puri; Tessa A Greenhalgh; James M Wilson; Jamie Franklin; Lia Mun Wang; Victoria Strauss; Chris Cunningham; Mike Partridge; Tim Maughan
Journal:  EJNMMI Res       Date:  2017-09-20       Impact factor: 3.138

6.  Oncogenic but non-essential role of N-myc downstream regulated gene 1 in the progression of esophageal squamous cell carcinoma.

Authors:  Wei Wei; Jacqueline C Bracher-Manecke; Xiaohang Zhao; Neil H Davies; Lanping Zhou; Runna Ai; Lisa Oliver; Francois Vallette; Denver T Hendricks
Journal:  Cancer Biol Ther       Date:  2012-11-28       Impact factor: 4.742

7.  Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry.

Authors:  L Dubois; W Landuyt; K Haustermans; P Dupont; G Bormans; P Vermaelen; P Flamen; E Verbeken; L Mortelmans
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

8.  Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?

Authors:  R Cooper; S Sarioğlu; S Sökmen; M Füzün; A Küpelioğlu; H Valentine; I B Görken; R Airley; C West
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

Review 9.  Bystander or no bystander for gene directed enzyme prodrug therapy.

Authors:  Gabi U Dachs; Michelle A Hunt; Sophie Syddall; Dean C Singleton; Adam V Patterson
Journal:  Molecules       Date:  2009-11-10       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.